These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23582767)

  • 1. Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.
    Pennock S; Kim D; Mukai S; Kuhnle M; Chun DW; Matsubara J; Cui J; Ma P; Maberley D; Samad A; Van Geest RJ; Oberstein SL; Schlingemann RO; Kazlauskas A
    Am J Pathol; 2013 May; 182(5):1659-70. PubMed ID: 23582767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.
    Pennock S; Haddock LJ; Mukai S; Kazlauskas A
    Am J Pathol; 2014 Nov; 184(11):3052-68. PubMed ID: 25261788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy.
    Lei H; Rheaume MA; Kazlauskas A
    Exp Eye Res; 2010 Mar; 90(3):376-81. PubMed ID: 19931527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth factors outside the PDGF family drive experimental PVR.
    Lei H; Velez G; Hovland P; Hirose T; Gilbertson D; Kazlauskas A
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3394-403. PubMed ID: 19324843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?
    Pennock S; Haddock LJ; Eliott D; Mukai S; Kazlauskas A
    Prog Retin Eye Res; 2014 May; 40():16-34. PubMed ID: 24412519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy.
    Lei H; Hovland P; Velez G; Haran A; Gilbertson D; Hirose T; Kazlauskas A
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2335-42. PubMed ID: 17460299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy.
    Lei H; Velez G; Hovland P; Hirose T; Kazlauskas A
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):42-8. PubMed ID: 18172073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel function of p53: a gatekeeper of retinal detachment.
    Lei H; Rheaume MA; Cui J; Mukai S; Maberley D; Samad A; Matsubara J; Kazlauskas A
    Am J Pathol; 2012 Sep; 181(3):866-74. PubMed ID: 22901751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy.
    Pennock S; Rheaume MA; Mukai S; Kazlauskas A
    Am J Pathol; 2011 Dec; 179(6):2931-40. PubMed ID: 22035642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses.
    Pennock S; Kazlauskas A
    Mol Cell Biol; 2012 May; 32(10):1955-66. PubMed ID: 22431518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
    Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
    Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor.
    Ikuno Y; Leong FL; Kazlauskas A
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3107-16. PubMed ID: 10967071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy.
    Zheng Y; Ikuno Y; Ohj M; Kusaka S; Jiang R; Cekiç O; Sawa M; Tano Y
    Jpn J Ophthalmol; 2003; 47(2):158-65. PubMed ID: 12738549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of thrombin in proliferative vitreoretinopathy.
    Bastiaans J; van Meurs JC; Mulder VC; Nagtzaam NM; Smits-te Nijenhuis M; Dufour-van den Goorbergh DC; van Hagen PM; Hooijkaas H; Dik WA
    Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4659-66. PubMed ID: 25015355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
    Ricker LJ; Dieudonné SC; Kessels AG; Rennel ES; Berendschot TT; Hendrikse F; Kijlstra A; La Heij EC
    Retina; 2012 Jan; 32(1):54-9. PubMed ID: 21836532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy.
    Praidou A; Klangas I; Papakonstantinou E; Androudi S; Georgiadis N; Karakiulakis G; Dimitrakos S
    Curr Eye Res; 2009 Feb; 34(2):152-61. PubMed ID: 19219687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of systemic renin-angiotensin-inhibition on ocular cytokines related to proliferative vitreoretinopathy.
    Hoerster R; Fauser S; Cursiefen C; Kirchhof B; Heindl LM
    Graefes Arch Clin Exp Ophthalmol; 2017 Sep; 255(9):1721-1725. PubMed ID: 28600710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy.
    Lei H; Velez G; Cui J; Samad A; Maberley D; Matsubara J; Kazlauskas A
    Am J Pathol; 2010 Jul; 177(1):132-40. PubMed ID: 20489144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
    Dieudonné SC; La Heij EC; Diederen RM; Kessels AG; Liem AT; Kijlstra A; Hendrikse F
    Ophthalmic Res; 2007; 39(3):148-54. PubMed ID: 17534114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy.
    Andrews A; Balciunaite E; Leong FL; Tallquist M; Soriano P; Refojo M; Kazlauskas A
    Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2683-9. PubMed ID: 10509666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.